VBL Therapeutics To Present Updated Clinical Results for VB-111 at 2011 American Society of Clinical Oncology Annual Meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present updated results for a Phase 1 study of VB-111 in patients with advanced metastatic cancer at the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place June 3-7, 2011, at McCormick Place in Chicago. Data from the trial evaluating the effect of VB-111 on 33 patients with advanced stage solid tumors demonstrate that VB-111 was well-tolerated and showed promising evidence of anti-tumor efficacy. The abstract for the poster (#3038) titled “A phase I trial of VB-111, a tissue- and condition-specific dual action vascular disruptive and antiangiogenic agent, for treatment of patients with advanced metastatic cancer,” is now available on the ASCO Annual Meeting website and will be presented on June 6, 2011 from 8 a.m. to noon CT.